-+ 0.00%
-+ 0.00%
-+ 0.00%

ACRIVON THERAPEUTICS ANNOUNCES POSITIVE ACR-368 PHASE 2B ENDOMETRIAL CANCER CLINICAL DATA WITH EU EXPANSION TO ACCELERATE ENROLLMENT, INITIAL ACR-2316 CLINICAL DATA, AND ACR-6840, ITS NEXT AP3-ENABLED DEVELOPMENT CANDIDATE, TARGETING CDK11

Reuters·01/08/2026 12:30:00

Please log in to view news